{
    "clinical_study": {
        "@rank": "99050", 
        "arm_group": [
            {
                "arm_group_label": "ALRN-5281 0.015 mg/kg", 
                "arm_group_type": "Experimental", 
                "description": "Dosage-0.015 mg/kg"
            }, 
            {
                "arm_group_label": "ALRN-5281 0.05 mg/kg", 
                "arm_group_type": "Experimental", 
                "description": "Dosage- 0.05 mg/kg"
            }, 
            {
                "arm_group_label": "ALRN-5281 0.15 mg/kg", 
                "arm_group_type": "Experimental", 
                "description": "Dosage- 0.15 mg/kg"
            }, 
            {
                "arm_group_label": "Placebo 0.015 mg/kg", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Dosage- 0.015 mg/kg"
            }, 
            {
                "arm_group_label": "Placebo 0.05 mg/kg", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Dosage- 0.05 mg/kg"
            }, 
            {
                "arm_group_label": "Placebo 0.15 mg/kg", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Dosage - 0.15 mg/kg"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of this study is to evaluate the safety and tolerability of a single\n      dose of ALRN-5281 administered by subcutaneous injection to healthy adult volunteers."
        }, 
        "brief_title": "Phase 1 Safety Study of ALRN-5281 in Healthy Subjects", 
        "completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "condition": "Growth Hormone Deficiency", 
        "condition_browse": {
            "mesh_term": [
                "Dwarfism, Pituitary", 
                "Endocrine System Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Healthy male or female subjects aged 20 to 50 years, inclusive, at the time of\n             informed consent.\n\n          2. Subjects must be in good health as determined by the Investigator based on detailed\n             medical history, physical examination, vital signs, clinical laboratory tests, ECGs\n             and other screening evaluations.\n\n          3. Ability to provide written informed consent and complying with all study requirements\n             and restrictions.\n\n          4. Is a non-smoker and non-tobacco user for a minimum of 6 months prior to screening\n\n        Exclusion Criteria:\n\n          1. History or current evidence of any clinically significant cardiac, endocrinologic,\n             hematologic, hepatobiliary, immunologic, metabolic, urologic, pulmonary, neurologic,\n             dermatologic, psychiatric, renal, or other major disease, as determined by the\n             Investigator\n\n          2. Previous treatment with any GH Releasing Hormone (GHRH) analog.\n\n          3. Participation in another clinical trial or treatment with an investigational agent\n             within 30 days or 5 half-lives, whichever is longer, prior to enrollment.\n\n          4. History of cancer within the past five years (excluding non-melanoma skin cancer).\n\n          5. History of alcohol or drug abuse or dependence within 12 months of screening as\n             determined by the Investigator.\n\n          6. Subjects with a body weight > 120 kg."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "33", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01775358", 
            "org_study_id": "ALRN-100-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "ALRN-5281 0.015 mg/kg", 
                "intervention_name": "ALRN-5281 0.015 mg/kg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "ALRN-5281 0.05 mg/kg", 
                "intervention_name": "ALRN-5281 0.05 mg/kg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "ALRN-5281 0.15 mg/kg", 
                "intervention_name": "ALRN-5281 0.15 mg/kg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo 0.015 mg/kg", 
                "intervention_name": "Placebo 0.015 mg/kg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo 0.05 mg/kg", 
                "intervention_name": "Placebo 0.05mg/kg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo 0.15 mg/kg", 
                "intervention_name": "Placebo 0.15mg/kg", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 29, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Overland Park", 
                    "country": "United States", 
                    "state": "Kansas", 
                    "zip": "66212"
                }, 
                "name": "Vince and Associates Clinical Research, LLC"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "6", 
        "official_title": "A Randomized, Single-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety and Tolerability of ALRN-5281 Administered by Subcutaneous Injection in Healthy Adult Volunteers", 
        "overall_official": [
            {
                "affiliation": "Vince and Associates", 
                "last_name": "Bradley D Vince, D.O.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Aileron Therapeutics", 
                "last_name": "Hubert C Chen, M.D.", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Incidence of adverse events", 
            "safety_issue": "No", 
            "time_frame": "28 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01775358"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Serum IGF-1", 
                "safety_issue": "No", 
                "time_frame": "Predose, Day 1-Day 28"
            }, 
            {
                "measure": "Serum GH", 
                "safety_issue": "No", 
                "time_frame": "Predose, Day 1-Day 28"
            }, 
            {
                "measure": "Time to Reach Maximum Observed Plasma Concentration (Tmax) of ALRN-5281", 
                "safety_issue": "No", 
                "time_frame": "Predose, Day 1- 0.5,1,2,3,4,6,8,10,12,14 and 16hr post dose , Day 2-Day11 and Day14"
            }, 
            {
                "measure": "Maximum plasma concentration (Cmax) of ALRN-5281", 
                "safety_issue": "No", 
                "time_frame": "Predose, Day 1- 0.5,1,2,3,4,6,8,10,12,14 and 16hr post dose , Day 2-Day11 and Day14"
            }, 
            {
                "description": "AUC (0-t)= Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-t)", 
                "measure": "Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)]", 
                "safety_issue": "No", 
                "time_frame": "Pre Dose, Day1- 0.5,1,2,3,4,6,8,10,12,14 and 16h post dose, Day2- Day11 and Day 14"
            }
        ], 
        "source": "Aileron Therapeutics", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Aileron Therapeutics", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}